US-based biotech firm Ocugen to establish R&D center in Hyderabad
NEW YORK/HYDERABAD: US-based biotechnology company Ocugen has on on Thursday announced its plan to establish a research and development (R&D) center in Telangana with an aim to focus on developing cutting-edge modifier gene therapies and regenerative cell therapy.
The announcement was made after IT and Industries Minister K. T. Rama Rao met with the chairman, CEO and co-founder of Ocugen Inc., Dr. Shankar Musunuri and his team.
Based out of Pennsylvania in United States, Ocugen, Inc. focuses on discovering, developing, and commercializing new treatment options to improve health and offer hope for patients across the globe through its innovations.
“We look forward to expanding operations in India and beginning to transform Ocugen into a truly global organization as we pursue new approaches to medicine—being bold and thinking differently with patients at the center of everything we do,” said Dr. Shankar Musunuri.
Minister K.T. Rama Rao said, "This is a testament to the vibrant biotech industry and a strong academic base in the state that has attracted both local and international players to establish research and development centers.”
Industries and Commerce Principal Secretary, Jayesh Ranjan; Chief Executive Officer of Telangana Life Sciences, Shakti M. Nagappan; Chief Scientific Officer, Head of Research, Development and Medical at Ocugen, Dr. Arun Upadhyay; and In Charge of the Ocugen India Project, Dr. Ajay Potluri were also present during the meeting.